Cubist Pharmaceuticals, Inc.
http://www.cubist.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cubist Pharmaceuticals, Inc.
Competitive Dealmaking Market Shifts To Smaller M&A, Partnering
Dollars spent on biopharma M&A so far in 2024 may not be as high as in 2023, but dealmakers say deal volume is robust with many factors influencing the overall value of transactions this year.
Asia Deal Watch: Chugai Extends Relationship With Helsinn
Plus deals involving Kissei/JWP, Shionogi/Cilcare, Takeda/Torrent, Genome & Co./Debiopharm, Kaken/J&J, CStone/Ewopharma, MediLink/BioNTech and more.
Three Gene Therapies, Moderna Metabolic Drug In Inaugural START Class; CBER Oversubscribes
Seven rare disease programs make up the first round of participants in the US FDA’s ‘Operation Warp Speed’-style program. Sponsors will benefit from ‘rapid, ad hoc’ communication with the agency.
BIO Notebook: FDA User Fees For AI Regulation, Partnering Strategy Evolves, And More
Insights from Day Two of the BIO International Convention in San Diego include the evolving pros and cons of partnering, user fees potentially supporting the FDA's AI ambitions, and J&J's view on dealmaking in 2024.
Company Information
- Industry
- Biotechnology
- Other Names / Subsidiaries
-
- Adolor Corporation (ADLR)
- Calixa Therapeutics, Inc.
- Optimer Pharmaceuticals, Inc.
- Trius Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice